Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Abstract

At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).

Keywords

Recombinant DNASpike (software development)VirologySpike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakCoronavirusMedicineBiologyComputer scienceInternal medicineBiochemistryInfectious disease (medical specialty)Gene

Affiliated Institutions

Related Publications

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey , Sue Ann Costa Clemens , Shabir A. Madhi +97 more

UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, ...

2020 The Lancet 4945 citations

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Markus Hoffmann , Hannah Kleine‐Weber , Nadine Krüger +3 more

Abstract The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviru...

2020 bioRxiv (Cold Spring Harbor Laboratory) 754 citations

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann , Hannah Kleine‐Weber , Simon Schroeder +10 more

2020 Cell 20901 citations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen , Di Wu , Wei Guo +17 more

BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is...

2020 Journal of Clinical Investigation 4983 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 24
Pages: 2320-2332
Citations: 1219
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1219

OpenAlex

Cite This

APA Style

                            
                                
                                    Cheryl Keech, 
                                
                                    Gary Albert, 
                                
                                    Iksung Cho
                                
                                et al.
                            
                            (2020). 
                            Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. 
                            New England Journal of Medicine
                            , 383
                            (24)
                            , 2320-2332.
                            https://doi.org/10.1056/nejmoa2026920
                        

Identifiers

DOI: 10.1056/nejmoa2026920